{"id":"https://openalex.org/W2779339208","doi":"https://doi.org/10.1212/wnl.90.15_supplement.s36.001","title":"Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (S36.001)","display_name":"Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (S36.001)","publication_year":2018,"publication_date":"2018-04-10","ids":{"openalex":"https://openalex.org/W2779339208","doi":"https://doi.org/10.1212/wnl.90.15_supplement.s36.001","mag":"2779339208"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.90.15_supplement.s36.001","doi":"https://doi.org/10.1212/wnl.90.15_supplement.s36.001","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.90.15_supplement.s36.001","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5104805489","display_name":"Stephen L. Hauser","orcid":"https://orcid.org/0000-0002-4932-4001","observed_orcids":["https://orcid.org/0000-0002-4932-4001"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Hauser","raw_affiliation_strings":["University of California, San Francisco San Francisco CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, San Francisco San Francisco CA United States","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054874316","display_name":"Ludwig Kappos","orcid":"https://orcid.org/0000-0003-4175-5509","observed_orcids":["https://orcid.org/0000-0003-4175-5509"]},"institutions":[{"id":"https://openalex.org/I1850255","display_name":"University of Basel","ror":"https://ror.org/02s6k3f65","country_code":"CH","type":"education","lineage":["https://openalex.org/I1850255"]},{"id":"https://openalex.org/I2802542264","display_name":"University Hospital of Basel","ror":"https://ror.org/04k51q396","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I2802542264"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Ludwig Kappos","raw_affiliation_strings":["University Hospital Basel, University of Basel Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital Basel, University of Basel Basel Switzerland","institution_ids":["https://openalex.org/I1850255","https://openalex.org/I2802542264"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031171090","display_name":"Xavier Montalb\u00e1n","orcid":"https://orcid.org/0000-0002-0098-9918","observed_orcids":["https://orcid.org/0000-0002-0098-9918"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Xavier Montalban","raw_affiliation_strings":["Vall d\u2019Hebron University Hospital Barcelona Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron University Hospital Barcelona Spain","institution_ids":["https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071219650","display_name":"Harold Koendgen","orcid":"https://orcid.org/0000-0002-8496-4952","observed_orcids":["https://orcid.org/0000-0002-8496-4952"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Harold Koendgen","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd Basel Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024306267","display_name":"Carrie Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Carrie Li","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd Basel Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045915531","display_name":"Carole Marcillat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Carole Marcillat","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd Basel Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039001065","display_name":"Ashish Pradhan","orcid":"https://orcid.org/0000-0002-2581-3038","observed_orcids":["https://orcid.org/0000-0002-2581-3038"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashish Pradhan","raw_affiliation_strings":["Genentech, Inc. South San Francisco CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc. South San Francisco CA United States","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108131221","display_name":"David Wormser","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"David Wormser","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd Basel Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5076338840","display_name":"Jerry S. Wolinsky","orcid":"https://orcid.org/0000-0002-8197-2762","observed_orcids":["https://orcid.org/0000-0002-8197-2762"]},"institutions":[{"id":"https://openalex.org/I919571938","display_name":"The University of Texas Health Science Center at Houston","ror":"https://ror.org/03gds6c39","country_code":"US","type":"education","lineage":["https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jerry Wolinsky","raw_affiliation_strings":["McGovern Medical School, UTHealth Houston TX United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"McGovern Medical School, UTHealth Houston TX United States","institution_ids":["https://openalex.org/I919571938"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.9502,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.72376595,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":97},"biblio":{"volume":"90","issue":"15_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ocrelizumab","display_name":"ocrelizumab","score":1.0},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.9900000095367432},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.968999981880188},{"id":"https://openalex.org/keywords/relapsing-multiple-sclerosis","display_name":"relapsing multiple sclerosis","score":0.8889999985694885},{"id":"https://openalex.org/keywords/primary-progressive-multiple-sclerosis","display_name":"primary progressive multiple sclerosis","score":1.0},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.8330000042915344},{"id":"https://openalex.org/keywords/clinical-trials","display_name":"clinical trials","score":0.550000011920929}],"concepts":[{"id":"https://openalex.org/C2778843634","wikidata":"https://www.wikidata.org/wiki/Q2013780","display_name":"Ocrelizumab","level":4,"score":0.9301024675369263},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.7716532945632935},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7127609848976135},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43422114849090576},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.3859350085258484},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38258153200149536},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.12181496620178223},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.0},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.90.15_supplement.s36.001","doi":"https://doi.org/10.1212/wnl.90.15_supplement.s36.001","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.90.15_supplement.s36.001","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389444731","https://openalex.org/W4389448283","https://openalex.org/W4389446879","https://openalex.org/W4389464675","https://openalex.org/W2996253774","https://openalex.org/W4281641263","https://openalex.org/W2904697613","https://openalex.org/W3198774415","https://openalex.org/W4388047647","https://openalex.org/W3203373156"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"report":[2],"ongoing":[3],"safety":[4,20,209,282],"evaluations":[5],"from":[6,40,200,206,374,601,626],"ocrelizumab":[7,43,137,160,193,201,286],"clinical":[8],"trials":[9,58],"and":[10,66,78,106,146,167,170,264,303,316,325,383,398,432,586],"open-label":[11],"extensions":[12],"(OLEs)":[13],"up":[14],"to":[15,31,213,632],"September":[16,273],"2017.":[17],"Background:":[18],"Ongoing":[19],"reporting":[21],"on":[22,142,159,216,339,361,412,444,470,496,522,548,571,583],"disease-modifying":[23],"therapies":[24],"for":[25,336,359,409,441,467,493,519,545,568,628],"multiple":[26],"sclerosis":[27],"(MS)":[28],"is":[29,290],"crucial":[30],"understanding":[32],"the":[33,67,115,190,285,297,301,362,388],"long-term":[34],"benefit\u2013risk":[35],"profile.":[36],"Data":[37,197],"are":[38,199],"reported":[39,215],"patients":[41,226],"receiving":[42,148],"in":[44,49,59,71,92,114,189,232,284,300],"one":[45],"Phase":[46,56,68,116,168],"II":[47,117],"study":[48,118],"relapsing-remitting":[50],"MS":[51,61,74,228,287],"(RRMS;":[52],"NCT00676715),":[53],"two":[54],"identical":[55],"III":[57,69],"relapsing":[60],"(RMS;":[62],"OPERA":[63,93],"I/II":[64,94],"[NCT01247324]/[NCT01412333])":[65],"trial":[70],"primary":[72],"progressive":[73],"(PPMS;":[75],"ORATORIO":[76,107],"[NCT01194570])":[77],"their":[79],"extensions.":[80],"Design/Methods:":[81],"Ocrelizumab":[82],"recipients":[83,202],"received":[84,119,229,333,357,371,406,438,464,490,516,542,565,598,618],"600":[85,120,138,143,194],"mg":[86,100,121,124,139,144,156],"doses":[87,111,130],"intravenously":[88],"every":[89],"24":[90,128],"weeks":[91],"(96":[95],"weeks;":[96,109],"first":[97],"dose:":[98],"2\u00d7300":[99],"infusions":[101,125],"split":[102],"by":[103,310,321],"14":[104],"days)":[105],"(\u2265120":[108],"all":[110],"split).":[112],"Patients":[113,183],"or":[122,150,154,178,345,418,450,476,502,528,554,577,589,596,622],"2000":[123,161],"through":[126,133,635],"Week":[127,134],"(both":[129],"split);":[131],"treatment":[132],"96":[135],"was":[136,319],"(patients":[140],"starting":[141,158],"dose":[145],"those":[147,204],"placebo":[149,165],"interferon":[151,171],"beta-1a":[152,172],"30\u03bcg)":[153],"1000":[155],"(those":[157],"mg).":[162],"Comparators":[163],"were":[164,245],"(ORATORIO":[166],"II)":[169],"(44\u03bcg":[173],"subcutaneous/three":[174],"times":[175],"weekly":[176],"[OPERA]":[177],"30\u03bcg":[179],"intramuscular/weekly":[180],"[Phase":[181],"II]).":[182],"completing":[184],"controlled-treatment":[185,298],"periods":[186],"could":[187],"enroll":[188],"OLE":[191],"with":[192,227,293,348,421,453,479,505,531,557,580],"mg/24":[195],"weeks.":[196],"presented":[198],"including":[203],"switching":[205],"comparators.":[207],"Long-term":[208],"data":[210,587],"will":[211,276],"continue":[212],"be":[214,277],"a":[217,272,340,413,445,471,497,523,549,572],"regular":[218],"basis.":[219],"Results:":[220],"As":[221],"of":[222,235,364,366,458,484,510,536],"February":[223],"2017,":[224],"2,301":[225],"ocrelizumab,":[230],"resulting":[231],"7,748":[233],"patient-years":[234,241],"exposure.":[236],"Reported":[237],"rates":[238],"per":[239],"100":[240],"(95%":[242],"confidence":[243],"interval)":[244],"as":[246],"follows:":[247],"adverse":[248],"events":[249],"(AEs),":[250],"226":[251],"(222\u2013229);":[252],"serious":[253,260],"AEs,":[254],"7.18":[255],"(6.59\u20137.80);":[256],"infections,":[257,261],"71.3":[258],"(69.5\u201373.2);":[259],"1.86":[262],"(1.57\u20132.19);":[263],"malignancy":[265],"0.454":[266],"(0.316\u20130.632).":[267],"Updated":[268],"cross-trial":[269],"information":[270],"using":[271],"2017":[274],"data-cut":[275],"presented.":[278],"Conclusions:":[279],"The":[280],"updated":[281],"profile":[283],"all-exposure":[288],"population":[289],"generally":[291],"consistent":[292],"that":[294],"seen":[295],"during":[296],"period":[299],"RMS":[302],"PPMS":[304],"populations.":[305],"Study":[306],"Supported":[307],"by:":[308],"Sponsored":[309],"F.":[311,379,558],"Hoffmann-La":[312,380,559],"Roche":[313,381,391,560],"Ltd;":[314],"writing":[315],"editorial":[317],"assistance":[318],"provided":[320],"Health":[322],"Interactions,":[323],"USA,":[324],"Articulate":[326],"Science,":[327],"UK.":[328],"Disclosure:":[329],"Dr.":[330,354,368,403,435,461,487,513,539,562,615],"Hauser":[331,355],"has":[332,356,370,405,437,463,489,515,541,564,581,592,597,617],"personal":[334,407,439,465,491,517,543,566],"compensation":[335,358,408,440,466,492,518,544,567],"consulting,":[337,410,442,468,494,520,546,569],"serving":[338,360,411,443,469,495,521,547,570],"scientific":[341,414,446,472,498,524,550,573],"advisory":[342,415,447,473,499,525,551,574,584],"board,":[343,416,448,474,500,526,552,575],"speaking,":[344,417,449,475,501,527,553,576],"other":[346,419,451,477,503,529,555,578],"activities":[347,420,452,478,504,530,556,579],"Symbiotix,":[349],"Annexon,":[350],"Bionure,":[351],"Molecular":[352],"Stethoscope.":[353],"Board":[363],"Directors":[365],"Neurona.":[367],"Kappos":[369],"research":[372],"support":[373],"Bayer":[375],"HealthCare":[376],"Pharmaceuticals,":[377,613],"Biogen,":[378,424,604],"Ltd":[382],"Genentech,Novartis,":[384],"Research":[385,392,401],"grants":[386],"from:":[387],"European":[389],"Union,":[390],"Foundation,":[393],"Swiss":[394,399],"Multiple":[395],"Sclerosis":[396],"Society":[397],"National":[400],"Foundation.":[402],"Montalban":[404],"Actelion,":[422],"Bayer,":[423],"Celgene,":[425],"Genzyme,":[426],"Merck,":[427],"Novartis,":[428],"Oryzon,":[429],"Roche,":[430],"Sanofi":[431],"Teva":[433],"Pharmaceutical.":[434],"Koendgen":[436],"I":[454,480,506,532],"am":[455,481,507,533],"an":[456,482,508,534],"Employee":[457,483,509,535],"F.Hoffann-La":[459],"Roche.":[460,486,512],"Li":[462],"F.Hoffmann-La":[485,511],"Marcillat":[488],"Pradhan":[514],"Genentech":[537],"Inc.":[538],"Wormser":[540],"Ltd.":[561],"Wolinsky":[563,616],"served":[582],"boards":[585],"monitoring":[588],"steering":[590],"committees,":[591],"held":[593],"consulting":[594],"agreements":[595],"speaker":[599],"honoraria":[600],"AbbVie,":[602],"Alkermes,":[603],"Bionest,":[605],"Clene":[606],"Nanomedicine,":[607],"EMD":[608],"Serono,":[609],"Forward":[610],"Pharma,":[611],"MedDay,":[612],"Nov.":[614],"royalty,":[619],"license":[620],"fees,":[621],"contractual":[623],"rights":[624],"payments":[625],"royalties":[627],"monoclonal":[629],"antibodies":[630],"out-licensed":[631],"Chemicon":[633],"International":[634],"UTHealth.":[636]},"counts_by_year":[{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":3}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2018-01-05T00:00:00"}